4//SEC Filing
Fordyce Marshall 4
Accession 0001415889-24-029964
CIK 0001831828other
Filed
Dec 19, 7:00 PM ET
Accepted
Dec 20, 4:06 PM ET
Size
28.9 KB
Accession
0001415889-24-029964
Insider Transaction Report
Form 4
Fordyce Marshall
DirectorPRESIDENT AND CEO
Transactions
- Exercise/Conversion
Class A Common Stock
2024-12-19$2.90/sh+57,661$167,032→ 143,603 total - Exercise/Conversion
Class A Common Stock
2024-12-18$2.90/sh+4,635$13,427→ 90,577 total - Sale
Class A Common Stock
2024-12-18$44.03/sh−4,635$204,094→ 85,942 total - Exercise/Conversion
Stock Option (Right to Buy)
2024-12-19−57,661→ 626,551 totalExercise: $2.90Exp: 2030-12-15→ Class A Common Stock (57,661 underlying) - Sale
Class A Common Stock
2024-12-18$43.52/sh−5,023$218,609→ 85,942 total - Exercise/Conversion
Stock Option (Right to Buy)
2024-12-18−15,625→ 686,087 totalExercise: $2.90Exp: 2030-12-15→ Class A Common Stock (15,625 underlying) - Sale
Class A Common Stock
2024-12-18$41.33/sh−3,772$155,883→ 85,942 total - Exercise/Conversion
Class A Common Stock
2024-12-18$2.90/sh+5,023$14,551→ 90,965 total - Exercise/Conversion
Class A Common Stock
2024-12-18$2.90/sh+1,875$5,432→ 87,817 total - Sale
Class A Common Stock
2024-12-18$43.81/sh−1,875$82,144→ 85,942 total - Exercise/Conversion
Class A Common Stock
2024-12-18$2.90/sh+2,195$6,358→ 88,137 total - Exercise/Conversion
Class A Common Stock
2024-12-18$2.90/sh+3,772$10,927→ 89,714 total - Sale
Class A Common Stock
2024-12-18$42.35/sh−2,195$92,949→ 85,942 total - Exercise/Conversion
Stock Option (Right to Buy)
2024-12-18−1,875→ 684,212 totalExercise: $2.90Exp: 2030-12-15→ Class A Common Stock (1,875 underlying)
Holdings
- 222,030(indirect: By GRAT)
Class A Common Stock
Footnotes (6)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 23, 2024.
- [F2]The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $40.87 to $41.82, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price.
- [F3]The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $41.88 to $42.74, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price.
- [F4]The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $42.88 to $43.87, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price.
- [F5]The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $43.88 to $44.32, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price.
- [F6]1/4 of the shares subject to the option vested on December 16, 2021, and 1/48 of the shares vest monthly thereafter.
Documents
Issuer
Vera Therapeutics, Inc.
CIK 0001831828
Entity typeother
Related Parties
1- filerCIK 0001859453
Filing Metadata
- Form type
- 4
- Filed
- Dec 19, 7:00 PM ET
- Accepted
- Dec 20, 4:06 PM ET
- Size
- 28.9 KB